Driving better diagnostic discovery for patients with Rebecca Middleton, vice chair of the participant panel at Genomics England The impact of genomics on global healthcare is one to watch.… In-vitro diagnostics | Next Generation Sequencing (NGS) | Uncategorised | Europe | IVD Gateway | Next Generation Sequencing (NGS)
Enabling faster diagnosis of rare diseases: Interview with HBA Support’s Rebecca Middleton As global research and the understanding of genomics grows… In-vitro diagnostics | Next Generation Sequencing (NGS) | Uncategorised | Europe | IVD Gateway | Next Generation Sequencing (NGS)
The future of thalassemia care The impact of genomics on global healthcare is one to watch.… In-vitro diagnostics | Next Generation Sequencing (NGS) | IVD Gateway | Next Generation Sequencing (NGS)
Most common cancer biomarkers for Europe NGS testing: RAS, BRAF, EGFR Most-commonly tested cancer biomarkers using NGS in Europe… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Larger gene panels are the predominant NGS testing strategy in EU5 Larger gene panels are the predominant NGS testing strategy… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Europe: precision medicine and access to NGS cancer biomarker testing Precision medicine and access to NGS cancer biomarker… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019 Proportion of cancer biomarker testing done with NGS… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Watch on-demand: Will Covid-19 Accelerate the Next Wave of Adoption of Next-Generation Sequencing (NGS) in Healthcare? Now, sequencing looks set to become even more integral in… Covid-19 testing | In-vitro diagnostics | Next Generation Sequencing (NGS) | Uncategorised | Global | IVD Gateway | Next Generation Sequencing (NGS)
The fastest-growing areas for LATAM’s next-generation sequencing market The next-generation sequencing (NGS) market is expected to… In-vitro diagnostics | Next Generation Sequencing (NGS) | Americas | IVD Gateway | Next Generation Sequencing (NGS)
The fastest-growing areas for APAC’s next-generation sequencing market The next-generation sequencing (NGS) market is expected to… In-vitro diagnostics | Next Generation Sequencing (NGS) | Asia | IVD Gateway | Next Generation Sequencing (NGS)
2022 healthcare megatrends shaping IVD 2022 healthcare megatrends shaping IVD… In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT) | Asia | Europe | Middle East & Africa | IVD Gateway | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT)
Keeping ahead of infectious diseases in Asia-Pacific with increased testing Our new briefing paper looks at the testing trends in… Covid-19 testing | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Asia | IVD Gateway | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT)